Sound Bioventures

"How Do You Do!": In collaboration with YVC - navigating mutual mentorship between CEOs and investors 📍 BIO-Europe® 🌍 Stockholm, Sweden 📆 November 4, 2024 🕖 17:00 – 18:00 Should mentorship be a two-way street between CEOs and biotech investors? This panel aims to uncover how CEOs and investors can significantly benefit from exchanging mentor roles and insights to drive collective success for biotech companies. Learn more about the dynamics of mutual mentorship, understand risks and rewards from engaging in reverse learning, and listen to investors and C-level professionals share real life experiences. Moderator: Philip Brainin, MD PhD MBA Panelists: Anta Gkelou Renee Aguiar-Lucander Bobby Soni Find out what else is on the agenda >> http://spr.ly/6044oqYfI #BIOEurope #Mentorship #CEOs #Investors YVC Collective

#BREAKING: Today, we are thrilled to announce the first participant has been dosed in the Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1), the industry’s first anti-microRNA therapeutic to be investigated in persons living with DM1. ATX-01 is an antimiR oligonucleotide designed to target microRNA 23b (miR-23b), which is involved in the pathogenesis of DM1. It has been demonstrated, in human DM1 primary myoblasts and in two murine models, that ATX-01 has a dual mechanism of action which reduces toxic DMPK mRNA and increases MBNL protein production. Click here to learn more: https://lnkd.in/gg2JWx3M Visit our #Patients page on our website too: https://lnkd.in/gVNxdQVH Learn more about the dual mechanism of our AntimiR™ technology here: https://lnkd.in/gnmFvjHv #RNAInnovation #MicroRNA #Biotech #MyotonicDystrophy #DM1 #FirstPatientDosed

#BREAKING: Today, we are thrilled to announce the first participant has been dosed in the Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1), the industry’s first anti-microRNA therapeutic to be investigated in persons living with DM1. ATX-01 is an antimiR oligonucleotide designed to target microRNA 23b (miR-23b), which is involved in the pathogenesis of DM1. It has been demonstrated, in human DM1 primary myoblasts and in two murine models, that ATX-01 has a dual mechanism of action which reduces toxic DMPK mRNA and increases MBNL protein production. Click here to learn more: https://lnkd.in/gg2JWx3M Visit our #Patients page on our website too: https://lnkd.in/gVNxdQVH Learn more about the dual mechanism of our AntimiR™ technology here: https://lnkd.in/gnmFvjHv #RNAInnovation #MicroRNA #Biotech #MyotonicDystrophy #DM1 #FirstPatientDosed

✨ Keynote Reveal!  We’re thrilled to announce that Philip Brainin, MD PhD MBA, Associate at Sound Bioventures, will be joining us as a keynote speaker at the Life Science Summit 2024: “Catalysts of Tomorrow”! A driving force in life science innovation and investment, Philip is passionate about empowering the next generation of life science companies. His expertise will shine as we dive into the future of VC’s role in healthcare and beyond. Philip’s words: “Thrilled to speak at the Life Science Summit 2024! Synapse fosters an inspiring environment to network and connect with the next generation of biotech professionals.” Don’t miss this exciting opportunity to learn from one of the visionaries shaping tomorrow’s innovations! 🗓 Event Date: October 15, 2024 | 16:30 - 20:30 📌 Location: The Park @ Forskaren, Solna, Stockholm ➡ Register now to secure your spot: https://lnkd.in/gDhgzFqx

"How Do You Do!": In collaboration with YVC - navigating mutual mentorship between CEOs and investors 📍 BIO-Europe® 🌍 Stockholm, Sweden 📆 November 4, 2024 🕖 17:00 – 18:00 Should mentorship be a two-way street between CEOs and biotech investors? This panel aims to uncover how CEOs and investors can significantly benefit from exchanging mentor roles and insights to drive collective success for biotech companies. Learn more about the dynamics of mutual mentorship, understand risks and rewards from engaging in reverse learning, and listen to investors and C-level professionals share real life experiences. Moderator: Philip Brainin, MD PhD MBA Panelists: Anta Gkelou Renee Aguiar-Lucander Bobby Soni Find out what else is on the agenda >> http://spr.ly/6044oqYfI #BIOEurope #Mentorship #CEOs #Investors YVC Collective

"At Teitur, our name captures the essence of our mission. Meaning “joyful” or “bright” in Old Norse, Teitur reflects our commitment to bringing light and hope to patients and families affected by Huntington’s and Parkinson’s diseases. " In this Sejelas Founder-CEO Interview series, we hear from Dr. Simon Mølgaard, the Co-Founder and CEO at Teitur Trophics. The Danish biotech team develops novel therapeutics for treating or preventing neurodegenerative diseases. Read the full article here: https://lnkd.in/gYxz45ZM #biotech #neuroscience #lifescience #sejelas #founderceo #interviewseries

"How Do You Do!": In collaboration with YVC - navigating mutual mentorship between CEOs and investors 📍 BIO-Europe® 🌍 Stockholm, Sweden 📆 November 4, 2024 🕖 17:00 – 18:00 Should mentorship be a two-way street between CEOs and biotech investors? This panel aims to uncover how CEOs and investors can significantly benefit from exchanging mentor roles and insights to drive collective success for biotech companies. Learn more about the dynamics of mutual mentorship, understand risks and rewards from engaging in reverse learning, and listen to investors and C-level professionals share real life experiences. Moderator: Philip Brainin, MD PhD MBA Panelists: Anta Gkelou Renee Aguiar-Lucander Bobby Soni Find out what else is on the agenda >> http://spr.ly/6044oqYfI #BIOEurope #Mentorship #CEOs #Investors YVC Collective

We present you the finalists for: 🏆 Women-Led Business Leader of the Year 🏆 ⭐Eliane Schutte, CEO, Xeltis ⭐Ann Meulemans, CEO, AbolerIS Pharma ⭐Barbara Angehrn Pavik, CEO, Asceneuron SA ⭐Pénélope Andreux, CSO, Vandria SA ⭐Agnès Arbat, CEO, OXOLIFE ⭐Maria Berruezo, Co-Founder and co-CEO, LactApp ⭐Cristiana Pires, CEO, Asgard Therapeutics ⭐Colleen Acosta, CEO, Freya Biosciences ⭐Ros Deegan, CEO, OMass Therapeutics ⭐Lisa Deschamps, CEO, AviadoBio _________ Want to be there to support your colleagues at the European Lifestars Awards, November 18? Book a ticket: https://lnkd.in/et72mQt5

Sound Bioventures is a venture capital fund investing in about-to-be clinical and clinical stage private companies in Europe and the USA developing novel medicines that address unmet medical needs. We focus on specialty therapeutic areas and diseases with significant clinical unmet need. My fellow founding partners, Johan Kördel and Bibhash Mukhopadhyay, and I started Sound Bioventures about three years ago. We raised $125m for our first fund out of which we are now investing. We first learned about Artax Biopharma (three years ago) during their Series B round. The management team pitched us on a new approach to autoimmune, one in which T cell response modulation via Nck seemed to make a lot of sense. They presented compelling in vitro and in vivo data to support the thesis, and they were looking to raise money for clinical trials with a lead asset. We then dug in and concluded that this was a very promising approach; if successful, it could create a true paradigm shift in how autoimmune diseases are treated. At Sound Bioventures, we wish to support ideas which can have the most impact for patients, so the Artax project fits very well. Execution by the new management team this year has been excellent. The Phase 2a patient trial in psoriasis is now fully recruited, on track for a data readout before year end. They’ve been doing a good job of getting the word out about Nck modulation and the AX-158 patient trial data coming in. When they knocked on the door to do a convertible financing round, we were all in. Now we are waiting for the data. It will be very interesting to see where the science takes us on this journey: does the patient readout confirm what the in vitro assays and animal models predicted? We have made the bet and can’t wait to see the data! - Casper Breum, managing partner at Sound Bioventures